Structural elucidation of a novel mechanism for the bacteriophage-based inhibition of the RNA degradosome

  1. An Van den Bossche  Is a corresponding author
  2. Steven W Hardwick
  3. Pieter-Jan Ceyssens
  4. Hanne Hendrix
  5. Marleen Voet
  6. Tom Dendooven
  7. Katarzyna J Bandyra
  8. Marc De Maeyer
  9. Abram Aertsen
  10. Jean-Paul Noben
  11. Ben F Luisi  Is a corresponding author
  12. Rob Lavigne  Is a corresponding author
  1. KU Leuven, Belgium
  2. University of Cambridge, United Kingdom
  3. Scietific Institute of Public Health, Belgium
  4. UHasselt, Belgium

Abstract

In all domains of life, the catalysed degradation of RNA facilitates rapid adaptation to changing environmental conditions, while destruction of foreign RNA is an important mechanism to prevent host infection. We have identified a virus-encoded protein termed gp37/Dip, which directly binds and inhibits the RNA degradation machinery of its bacterial host. Encoded by giant phage ΦKZ, this protein associates with two RNA binding sites of the RNase E component of the Pseudomonas aeruginosa RNA degradosome, occluding them from substrates and resulting in effective inhibition of RNA degradation and processing. The 2.2 Å crystal structure reveals that this novel homo-dimeric protein has no identifiable structural homologues. Our biochemical data indicate that acidic patches on the convex outer surface bind RNase E. Through the activity of Dip, ΦKZ has evolved a unique mechanism to down regulate a key metabolic process of its host to allow accumulation of viral RNA in infected cells.

Data availability

The following data sets were generated
    1. Steven Hardwick
    (2016) crystal structure
    Publicly available at the RCSB Protein Data Bank (accession no: 5FT1).
    1. An Van den Bossche
    2. Jean-Paul Noben
    (2015) Mass spectrometry data set
    Publicly available at the PRIDE Archive (accession no: PXD003285).

Article and author information

Author details

  1. An Van den Bossche

    Laboratory of Gene Technology, KU Leuven, Leuven, Belgium
    For correspondence
    An.vandenbossche@wiv-isp.be
    Competing interests
    The authors declare that no competing interests exist.
  2. Steven W Hardwick

    Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Pieter-Jan Ceyssens

    Division of Bacterial diseases, Scietific Institute of Public Health, Brussels, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  4. Hanne Hendrix

    Laboratory of Gene Technology, KU Leuven, Leuven, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  5. Marleen Voet

    Laboratory of Gene Technology, KU Leuven, Leuven, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  6. Tom Dendooven

    Laboratory of Gene Technology, KU Leuven, Leuven, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  7. Katarzyna J Bandyra

    Department of Biochemsitry, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Marc De Maeyer

    Biochemistry, Molecular and Structural Biology Scetion, KU Leuven, Leuven, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  9. Abram Aertsen

    Laboratory of Microbiology, KU Leuven, Leuven, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  10. Jean-Paul Noben

    Biomedical Research Institute and Transnational University Limburg, UHasselt, Diepenbeek, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  11. Ben F Luisi

    Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom
    For correspondence
    bfl20@cam.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
  12. Rob Lavigne

    Laboratory of Gene Technology, KU Leuven, Leuven, Belgium
    For correspondence
    rob.lavigne@biw.kuleuven.be
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7377-1314

Funding

Fonds Wetenschappelijk Onderzoek (G.0599.11 & Scolarship AV)

  • An Van den Bossche
  • Pieter-Jan Ceyssens
  • Hanne Hendrix
  • Rob Lavigne

Agentschap voor Innovatie door Wetenschap en Technologie (SBO 100042)

  • An Van den Bossche
  • Pieter-Jan Ceyssens
  • Rob Lavigne

Onderzoeksraad, KU Leuven (CREA/09/017 & IDO/10/012)

  • Abram Aertsen
  • Rob Lavigne

Wellcome Trust (scholarship SH, BL)

  • Steven W Hardwick
  • Ben F Luisi

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2016, Van den Bossche et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,642
    views
  • 530
    downloads
  • 51
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. An Van den Bossche
  2. Steven W Hardwick
  3. Pieter-Jan Ceyssens
  4. Hanne Hendrix
  5. Marleen Voet
  6. Tom Dendooven
  7. Katarzyna J Bandyra
  8. Marc De Maeyer
  9. Abram Aertsen
  10. Jean-Paul Noben
  11. Ben F Luisi
  12. Rob Lavigne
(2016)
Structural elucidation of a novel mechanism for the bacteriophage-based inhibition of the RNA degradosome
eLife 5:e16413.
https://doi.org/10.7554/eLife.16413

Share this article

https://doi.org/10.7554/eLife.16413

Further reading

    1. Biochemistry and Chemical Biology
    2. Computational and Systems Biology
    A Sofia F Oliveira, Fiona L Kearns ... Adrian J Mulholland
    Short Report

    The spike protein is essential to the SARS-CoV-2 virus life cycle, facilitating virus entry and mediating viral-host membrane fusion. The spike contains a fatty acid (FA) binding site between every two neighbouring receptor-binding domains. This site is coupled to key regions in the protein, but the impact of glycans on these allosteric effects has not been investigated. Using dynamical nonequilibrium molecular dynamics (D-NEMD) simulations, we explore the allosteric effects of the FA site in the fully glycosylated spike of the SARS-CoV-2 ancestral variant. Our results identify the allosteric networks connecting the FA site to functionally important regions in the protein, including the receptor-binding motif, an antigenic supersite in the N-terminal domain, the fusion peptide region, and another allosteric site known to bind heme and biliverdin. The networks identified here highlight the complexity of the allosteric modulation in this protein and reveal a striking and unexpected link between different allosteric sites. Comparison of the FA site connections from D-NEMD in the glycosylated and non-glycosylated spike revealed that glycans do not qualitatively change the internal allosteric pathways but can facilitate the transmission of the structural changes within and between subunits.

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Conor J Howard, Nathan S Abell ... Nathan B Lubock
    Research Article

    Deep Mutational Scanning (DMS) is an emerging method to systematically test the functional consequences of thousands of sequence changes to a protein target in a single experiment. Because of its utility in interpreting both human variant effects and protein structure-function relationships, it holds substantial promise to improve drug discovery and clinical development. However, applications in this domain require improved experimental and analytical methods. To address this need, we report novel DMS methods to precisely and quantitatively interrogate disease-relevant mechanisms, protein-ligand interactions, and assess predicted response to drug treatment. Using these methods, we performed a DMS of the melanocortin-4 receptor (MC4R), a G-protein-coupled receptor (GPCR) implicated in obesity and an active target of drug development efforts. We assessed the effects of >6600 single amino acid substitutions on MC4R’s function across 18 distinct experimental conditions, resulting in >20 million unique measurements. From this, we identified variants that have unique effects on MC4R-mediated Gαs- and Gαq-signaling pathways, which could be used to design drugs that selectively bias MC4R’s activity. We also identified pathogenic variants that are likely amenable to a corrector therapy. Finally, we functionally characterized structural relationships that distinguish the binding of peptide versus small molecule ligands, which could guide compound optimization. Collectively, these results demonstrate that DMS is a powerful method to empower drug discovery and development.